Eisai – Sponsored Industry Symposium

The evolving HCC treatment landscape: what is the role of LENVIMA® (lenvatinib) monotherapy in first-line uHCC?

Saturday 12th September, 2:00 PM (CEST)

Eisai are proud to be a principle partner for ILCA 2020 and welcome you to join the following symposium:

The evolving HCC treatment landscape: what is the role of LENVIMA® (lenvatinib) monotherapy in first-line uHCC?

The systemic treatment landscape for HCC is constantly evolving.1 Over recent years, various treatments have been approved for uHCC, including tyrosine kinase inhibitors and immunotherapies.1 As combination therapy* has now been added to the treatment armamentarium for uHCC,1 one of the key discussion points is around the role of monotherapy as a first-line treatment.

In this symposium, Professor Andrew Zhu and Professor Arndt Vogel will discuss the role of LENVIMA® monotherapy in the rapidly evolving uHCC treatment landscape. This will include discussions around patient selection and clinical considerations in the first-line setting as well as an overview of the latest clinical data for LENVIMA® monotherapy.

The symposium will be streamed on the ILCA 2020 virtual conference platform on Saturday 12th September and will also be available on demand.

Agenda

Time Activity Speakers
14.00–14.50 The evolving HCC treatment landscape: what is the role of LENVIMA© monotherapy in first-line uHCC?
Professor Zhu
Professor Vogel
the role of LENVIMA© monotherapy in first-line uHCC?
What did we learn when results for REFLECT were released?
What have we learnt following REFLECT?
14.50–15.00 Live Q&A session Professor Zhu
Professor Vogel

Meet the speakers

Professor Andrew Zhu
Professor of Medicine at Harvard Medical School, USA

Director Emeritus of Liver Cancer Research at Massachusetts General Hospital, USA
Director at the Jiahui International Cancer Center, Shanghai, China

Professor Arndt Vogel
Professor for Gastrointestinal Oncology at the Hannover Medical School, Germany

* Not EMA-approved.
HCC: hepatocellular carcinoma, uHCC: unresectable hepatocellular carcinoma.
1.    Roderburg C et al. Hepat Oncol 2020;7(2) doi: 10.2217/hep-2020-0004
The materials for LENVIMA® produced by Eisai for this virtual conference are approved for UK healthcare professionals and other relevant decisions makers. LENVIMA® is indicated in the UK as monotherapy for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have received no prior systemic therapy.

For the full UK prescribing information, go to the following link: eisaihcc.com. Prescribing information may vary depending on local approval for each country. Therefore, before prescribing any product, always refer to local materials such as the prescribing information and/or the Summary of Prescribing Characteristics (SPC).

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for the MHRA Yellow Card in the Google Play or Apple App Store, or Ireland: www.hpra.ie. Adverse events should also be reported to Eisai Ltd on +44 (0)845 676 1400/+44 (0)208 600 1400 or [email protected]

GL-LENA-20-00040
August 2020